Unveiling the Top 5 Powerhouse Life Science ETFs of 2024!

1. DEPRO Global X Longevity Thematic ETF: One of the top-ranking life science ETFs in 2024 is the DEPRO Global X Longevity Thematic ETF. This ETF focuses on the longevity economy, investing in companies that will benefit from the rising global aging and extended lifespan trend. The companies supported by DEPRO are involved in biotechnology, healthcare, technology, and consumer services for seniors. This includes healthcare companies that concentrate on age-related diseases, like Alzheimer’s and heart disease. DEPRO has an impressive growth rate with a total asset base of over $1.5 billion and an expense ratio of 0.50%. 2. iShares Nasdaq Biotechnology ETF (IBB): With over $9 billion in assets, IBB is one of the largest ETFs in the biotechnology sector. It tracks the NASDAQ Biotechnology Index, effectively exposing investors to firms that are listed on the NASDAQ and are either classified as biotechnology or pharmaceutical. Its primary focus is on high-growth companies engaged in the use of biological processes to develop products and services. However, the portfolio is not restricted to only small cap biotech firms, but also includes many large, well-established companies like Amgen and Gilead Sciences. 3. Health Care Select Sector SPDR Fund (XLV): XLV is an exchange-traded fund launched in 1998 with a focus on healthcare. It currently has an asset base of over $22 billion. The fund provides precise exposure to companies in pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology. It has an expense ratio of 0.12%, making it a cost-effective option. Also, investors have been drawn to its steady performance over the years and a fairly stable number of healthcare giants. 4. ARK Genomic Revolution Multi-Sector ETF (ARKG): This ETF is known for its focus on CRISPR, gene editing, therapeutics, and agricultural bioengineering. Its investments are also concentrated on the advancements in genomics and the possibilities therein. Companies in ARKG’s portfolio are mainly those dedicating substantial resources to health-related genetic technology. The ETF has an exceptional performance record with an over 80% increase in 2023. Despite a higher expense ratio of 0.75%, the high yield return makes it an attractive choice for investors. 5. VanEck Vectors Biotech ETF (